Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
multiple myeloma
Pharma
UPDATED: FDA advisers back Carvykti, Abecma in earlier myeloma
The FDA's outside advisers voted that the early deaths seen in the two CAR-Ts' trials are an acceptable risk compared to the drugs' benefits.
Angus Liu
Mar 15, 2024 1:58pm
FDA flags early deaths for multiple myeloma CAR-Ts
Mar 13, 2024 11:06am
Legend CEO offers preview of high-stakes FDA adcomm for Carvykti
Mar 11, 2024 1:29pm
With GSK's 2nd Blenrep win, analysts see blockbuster comeback
Mar 7, 2024 10:14am
FDA revokes approval of Oncopeptides' Pepaxto
Feb 23, 2024 11:10am
GSK details combo data that could bring Blenrep back to life
Feb 5, 2024 5:00pm